|1.||Preziosi, Marie-Pierre: 2 articles (11/2015 - 11/2015)|
|2.||Messonnier, Nancy: 2 articles (11/2015 - 01/2008)|
|3.||Viviani, Simonetta: 2 articles (11/2015 - 09/2007)|
|4.||Mbakuliyemo, Nehemie: 2 articles (11/2015 - 11/2015)|
|5.||Diomandé, Fabien V K: 2 articles (11/2015 - 11/2015)|
|6.||Djingarey, Mamoudou H: 2 articles (11/2015 - 11/2015)|
|7.||Nadel, Simon: 2 articles (12/2011 - 08/2002)|
|8.||Wilder-Smith, Annelies: 2 articles (11/2011 - 10/2007)|
|9.||Centers for Disease Control and Prevention (CDC): 2 articles (08/2010 - 09/2009)|
|10.||Kieft, Charlotte: 2 articles (02/2008 - 01/2007)|
09/01/1980 - "Protective efficacy of a bivalent (A + C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda."
12/01/1999 - "For the entire meningitis belt, routine coverage with the 1- or 4-dose schedule meningococcal vaccine would require 4.9 and 19.6 million doses annually, respectively, for an annual net cost of $4.4 to $12.3 million and prevent an average 10300 to 12600 cases (23 to 28%), assuming a long term vaccine efficacy of 50%. "
06/01/1973 - "A controlled field trial of a serogroup A meningococcal polysaccharide vaccine was conducted at three locations in Egypt during the winter cerebrospinal meningitis (CSM) season of 1971-72. "
01/01/1973 - "A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A."
11/15/2015 - "During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated. "
03/01/2001 - "influenzae type b, and meningococcal vaccines have reduced the incidence of infections in asplenic-hyposplenic individuals, but even these measures have not eliminated the risk. "
11/15/2005 - "Because 70 to 80 percent of these infections in the United States are caused by meningococcal serogroups C, Y, and W-135, which are contained in the tetravalent meningococcal vaccines, they are potentially preventable. "
08/01/2002 - "The success of immunisation against Haemophilus influenzae type b infection is being mirrored with serogroup C conjugated meningococcal vaccine and pneumococcal conjugate vaccine. "
12/12/2001 - "Despite these exciting prospects, serogroup B meningococci still account for a majority of infections in industrialised nations but development of safe, immunogenic and effective serogroup B meningococcal vaccines has been an elusive goal. "
08/08/2001 - "Infections were potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year olds, 68.1% of those younger than 15 years, and 76.8% of adults aged 25 years or older. "
09/01/2015 - "Conjugate meningococcal vaccines have been shown to be more effective in preventing meningococcal infection in young children. "
04/01/2000 - "Future studies will need to focus on the potential vaccine prevention of the increased risk of meningococcal infection in persons of high school age, particularly as new conjugate meningococcal vaccines become available."
03/01/2003 - "As more effective meningococcal vaccines become available, recommendations for their use in nonepidemic settings should consider current epidemiologic trends, particularly changes in age and serogroup distribution of meningococcal infections."
01/01/2002 - "[Menomune: a tetravalent vaccine for the prophylaxis of meningococcal infections of types A, C, W135, Y]."
01/01/1993 - "We describe here the presentation and clinical course of systemic meningococcal infection in two HIV-1-seropositive men and the response to meningococcal vaccine in one. "
|4.||Human Influenza (Influenza)
06/01/2002 - "Coverage of pneumococcal vaccine (88%) was higher than that of Haemophilus influenza type b (Hib) conjugate vaccine (70%) or meningococcal vaccine (51%). "
06/01/2005 - "Updates on immunizations, including varicella and pneumococcus in the post-vaccine era, use of a polyvalent conjugated meningococcal vaccine, and influenza vaccination during a vaccine shortage are discussed. "
12/01/2010 - "The objective of this study was to evaluate the efficacy of influenza and meningococcal vaccines in healthy subjects exposed to the anti-interleukin-1β (anti-IL-1β) monoclonal antibody canakinumab. "
10/15/2006 - "The introduction of immunization with polyvalent pneumococcal, Hemophilus Influenza and meningococcal vaccines significantly cut down the incidence of post-splenectomy sepsis and mortality. "
04/09/1997 - "To describe the frequency and patterns of use of routine childhood and hepatitis B, pneumococcal, influenza, and meningococcal vaccines following allogeneic bone marrow transplantation (BMT). "
08/07/1982 - "Many studies have demonstrated the efficacy of meningococcal vaccine in nonepidemic meningococcal meningitis, but few have examined its efficacy in epidemic conditions. "
12/01/2011 - "In those parts of the world that have introduced conjugate meningococcal vaccines, there has been a significant change in the epidemiology of meningococcal meningitis. "
01/01/2003 - "Endemic and epidemic group A meningococcal meningitis remains a major cause of morbidity and mortality in sub-Saharan Africa, despite the availability of the safe and inexpensive group A meningococcal polysaccharide vaccine, which is protective at all ages when administered as directed. "
11/01/2002 - "Search terms included, but were not limited to, meningococcal vaccines, meningococcal meningitis, meningococcal infection, and meningococcus. "
06/21/2003 - "The beginning of this millennium has witnessed the virtual disappearance of Haemophilus invasive disease in some countries, emergence of pneumococcal strains that are resistant to multiple antibiotics, isolation of pneumococci with tolerance to vancomycin, outbreaks and clusters of meningococcal meningitis in several geographical areas, and intense research in development of effective conjugate pneumococcal and meningococcal vaccines. "
|4.||Tetanus Toxoid (Vaccine, Tetanus)
|5.||Diphtheria Toxoid (Vaccine, Diphtheria)
|7.||Immunologic Factors (Immunomodulators)
|8.||Meningococcal Vaccines (Meningococcal Vaccine)
|9.||Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
|10.||Complement System Proteins (Complement)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)